Celltrion Inc. Enters CDMO Arena Amid Shifts in Global Biosecurity Landscape
South Korea’s biosimilars giant, Celltrion Inc., is gearing up to expand into the contract development...
Celltrion
Hasten Biopharmaceutical Expands into Pan-Asia Regions with Celltrion Asset Acquisition
Hasten Biopharmaceutical Co., Ltd, a China-based pharmaceutical company backed by CBC Group, has announced an...
Dr. Reddy’s Launches Biosimilar Versavo in UK to Challenge Roche’s Cancer Therapy Avastin
Dr. Reddy’s Laboratories (NYSE: RDY), a prominent Indian pharmaceutical company, has launched its biosimilar Versavo...
Celltrion’s Infliximab Biosimilar Shows Promising Long-Term Efficacy and Safety in CD and UC
South Korean biopharmaceutical company Celltrion (KRX: 068270) has presented positive long-term efficacy and safety data...
WuXi XDC Partners with Celltrion to Support Global Development and Manufacturing of Bioconjugated Drugs
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
Cordavis Launches First Biosimilar: Novartis’ Hyrimoz to Compete with Humira
Swiss pharmaceutical giant Novartis (NYSE: NVS) unit Sandoz’s biosimilar product, Hyrimoz (adalimumab), which references AbbVie’s...